文献速递细菌感染、耐药与抗菌药物医院感染防控

免疫功能低下患者缩短抗生素疗程:不可能实现的梦想?

Shorter antibiotic courses in the immunocompromised: the impossible dream?
PubMed 文献 · Clin Microbiol Infect · 2022-08-19

综述评估实体器官移植受者和中性粒细胞减少性发热综合征患者缩短抗生素疗程的研究,多数移植研究为回顾性但临床相关终点相似,随机研究显示以临床改善为指导的短疗程与发热复发率和死亡率相似,作者认为应考虑短疗程并优先开展随机对照试验。

要点

  • 器官移植受者中多数缩短疗程研究为回顾性,临床相关终点发生率相似。
  • 中性粒细胞减少性发热患者已有随机研究,但人群和评估结局异质。
  • 以临床改善为指导的短疗程与发热复发率和死亡率相似。

核心结论

  • 作者认为,与免疫功能正常患者的研究类似,免疫功能低下宿主疑似细菌感染时应考虑缩短抗生素疗程。
  • 作者建议器官移植受者和中性粒细胞减少性发热综合征患者应优先纳入评估短疗程治疗的随机对照临床试验。

研究设计与样本

  • 综述检索PubMed、Embase、MEDLINE和临床指南文件,评估实体器官移植受者和接受抗肿瘤化疗或造血细胞移植患者中性粒细胞减少性发热综合征的短疗程抗生素研究。

主要发现

  • 器官移植受者中多数评估短疗程抗生素结局的研究为回顾性,但临床相关终点发生率相似。
  • 高危和低危中性粒细胞减少性发热患者已被充分研究,包括纳入随机研究,但患者人群和评估结局异质。
  • 以临床改善为指导采用短疗程与更少抗生素使用天数相关,且发热复发率和死亡率相似。

临床怎么用

  • 作者认为,免疫功能低下宿主疑似细菌感染时应考虑缩短抗生素疗程。
  • 作者建议器官移植受者和中性粒细胞减少性发热综合征患者应优先纳入评估短疗程治疗的随机对照临床试验。

局限性

  • 器官移植受者中多数评估短疗程抗生素结局的研究为回顾性。
  • 中性粒细胞减少性发热的随机研究患者人群和评估结局异质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A growing number of studies have demonstrated similar outcomes with shorter courses of antibiotics for bacterial infections. Immunocompromised patients are frequently excluded from these studies despite anticipated benefits associated with shortening antibiotic courses (including lower risks of antibiotic toxicity, Clostridioides difficile infection, drug-resistant pathogens, and microbiome alterations). OBJECTIVES: To critically review the literature that assesses shorter antibiotic courses in immunocompromised patients, specifically among solid organ transplant recipients and neutropenic fever (NF) syndromes among patients on antineoplastic chemotherapy and undergoing haematopoietic cell transplant. SOURCES: References were identified through searches of PubMed, Embase, MEDLINE, and clinical guidelines documents. CONTENT: Among organ transplant recipients, the majority of studies assessing outcomes associated with shorter antibiotic courses have been retrospective but have demonstrated similar rates of clinically relevant endpoints. Patients with high- and low-risk NF have been well-studied, including enrolment in randomized studies, albeit with heterogeneous patient populations and outcomes assessed. Clinical improvement-guided adoption of shorter courses has been associated with fewer antibiotic days and similar rates of fever recurrence and mortality. IMPLICATIONS: Similar to studies demonstrating efficacy in immunocompetent patients, shorter antibiotic courses should be considered for immunocompromised hosts with presumed bacterial infections. Organ recipients and patients with NF syndromes should be prioritized for study in randomized controlled clinical trials assessing shorter course therapy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Imlay H, Laundy NC, Forrest GN, et al. Shorter antibiotic courses in the immunocompromised: the impossible dream? Clin Microbiol Infect. 2022. PMID: 35988852. doi:10.1016/j.cmi.2022.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。